The substances or metabolites mentioned encompass -aminobutyric acid (GABA), 5-HT, DA, norepinephrine, acetylcholine, histamine, SCFAs, and others (113, 114)
National Institute of Health (NIH), after analyzing weights and cardiovascular, metabolic risk factors a year after suspending the Wegovy treatment, patients regained two-thirds of the lost weight on average, and their cardiovascular, metabolic risk factors also returned to similar levels to changed weights
Meta-analyses show that semaglutide increases the likelihood of discontinuing treatment (relative risk 1.67, 95% CI 1.27-2.21), primarily due to gastrointestinal adverse events
Discuss any persistent or severe GI side effects with your provider in some cases, a slower titration schedule is the right solution rather than discontinuing therapy entirely